The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.6M data for 1.1M Compounds and 8.10K Targets. Of those, 1,205K data for 557K Compounds and 4.4K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to you in 2022, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

9 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

Article Title
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.EBI
University of Washington
Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors.EBI
Chinese Academy of Sciences
The discovery of small molecule chemical probes of Bcl-X(L) and Mcl-1.EBI
EntreMed Inc.
Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.EBI
Universit£ Paris-Saclay
Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.EBI
Hunan Provinc
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.EBI
University of Maryland
Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.BDB
Eli Lilly and Company
Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound.BDB
Kyowa Hakko Kogyo Co., Ltd